VedaBio Emerges From Stealth With $40m For CRISPR-driven Molecular Detection

प्लेटो द्वारा पुनर्प्रकाशित

अनुयायियों: 0

VedaBio has launched from stealth mode alongside an initial funding of more than $40m backed by lead investor OMX Ventures, with the company saying it is poised to drive a new way of molecular detection.

The company debuted with CRISPR Cascade – a platform that can detect genetic code without the need for target amplification. Target amplification – the most common type being polymerase chain reaction (PCR) – is usually needed to make more copies of nucleic acid so it can be detected.

According to US-based VedaBio, its platform maintains PCR-level accuracy whilst eliminating the need for an amplification step. The company says the analytical turnaround time for the detection platform is less than one minute.

Molecular testing is used for diagnosis of certain conditions or utilised to predict risk of future disease.

VedaBio co-founder and CEO Anurup Ganguli said: “With the CRISPR Cascade reaction, we have unlocked the true power of CRISPR with a platform that delivers near-instant molecular detection of highly multiplexed analytes.”

Ganguli added that the platform could help make strides in research and industrial tools, in addition to diagnostics and therapeutics.

ग्लोबलडेटा द्वारा संचालित, बाज़ार में सबसे व्यापक कंपनी प्रोफाइल तक पहुंचें। शोध के घंटे बचाएं. प्रतिस्पर्धात्मक बढ़त हासिल करें.

कंपनी प्रोफाइल - निःशुल्क नमूना

शुक्रिया!

आपका डाउनलोड ईमेल शीघ्र ही आ जाएगा

हम अपनी कंपनी प्रोफाइल की अनूठी गुणवत्ता के बारे में आश्वस्त हैं। हालाँकि, हम चाहते हैं कि आप अपने व्यवसाय के लिए सबसे अधिक लाभकारी निर्णय लें, इसलिए हम एक निःशुल्क नमूना पेश करते हैं जिसे आप नीचे दिए गए फॉर्म को सबमिट करके डाउनलोड कर सकते हैं।

ग्लोबलडेटा द्वारा

The CRISPR-enabled molecular detection space saw significant attention when Mammoth Biosciences was given an early use authorisation by the US Food and Drug Administration (FDA) for its CRISPR-based SARS-CoV-2 molecular assay. According to GlobalData’s deal database, Mammoth Biosciences has raised around $263m in seed financing.

शर्लक बायोसाइंसेस, also a market player that has amassed over $110m in funding, opened a new UK biomanufacturing facility in August 2023.